Brokerages Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $7.06

Shares of Vor Biopharma Inc. (NYSE:VOR) have been given an average recommendation of “Hold” by the ten research firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $7.06.

Several analysts have commented on the stock. Wedbush reiterated a “neutral” rating and set a $0.40 target price (down previously from $7.00) on shares of Vor Biopharma in a research report on Thursday, May 8th. Stifel Nicolaus dropped their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Baird R W cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Oppenheimer restated an “outperform” rating and issued a $8.00 price objective on shares of Vor Biopharma in a research report on Friday, March 21st. Finally, HC Wainwright restated a “neutral” rating on shares of Vor Biopharma in a research report on Friday, May 9th.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock opened at $0.19 on Friday. The firm has a fifty day moving average of $0.57 and a two-hundred day moving average of $0.93. The stock has a market capitalization of $23.34 million, a price-to-earnings ratio of -0.11 and a beta of -0.21. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $1.80.

Institutional Trading of Vor Biopharma

A number of large investors have recently made changes to their positions in VOR. Two Sigma Investments LP increased its holdings in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares in the last quarter. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Vor Biopharma during the 4th quarter worth about $33,000. Northern Trust Corp increased its holdings in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Vor Biopharma during the 4th quarter worth about $60,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.